Hepion Pharmaceuticals is a US-based biopharmaceutical company dedicated to developing drug therapy for chronic liver diseases, such as non-alcoholic steatohepatitis (NASH). Its main asset is Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials. The company was incorporated in 2013 and was previously known as ContraVir Pharmaceuticals.